Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.08+0.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ENTA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | 65.3 | 65.3 | 67.6 | 79.2 | 86.2 | 97.1 | 122.5 | 205.2 | 206.6 | 102.8 | 88.3 | 160.9 | 47.7 | 32.1 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 102.8 | 88.3 | 160.9 | 47.7 | 32.1 |
| Operating Expenses & Income | ||||||||||||||
| R&D Expenses | 86.2 | 106.7 | 131.5 | 163.5 | 164.5 | 174.1 | 136.8 | 142.2 | 94.9 | 57.5 | 40.5 | 23.2 | 18.7 | 16.8 |
| Operating Income | (58.7) | (85.3) | (121.7) | (137.2) | (123.8) | (109.6) | (41.6) | 36.7 | 88.3 | 24.6 | 30.8 | 124.1 | 19.0 | 9.0 |
| Earnings from Continuing Operations | ||||||||||||||
| Interest Expense | — | 7.7 | 10.9 | 5.1 | 0.0 | 0.0 | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | 2.5 | 1.7 | 1.0 | 0.5 | 0.2 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | (2.5) | (1.7) | (1.0) | (0.4) | (0.2) |
| Other Non-Operating Income / Expenses | (4.4) | 1.8 | 3.9 | 6.2 | 1.7 | 2.0 | 6.6 | 8.8 | 4.8 | 2.3 | 1.7 | 1.3 | 0.3 | 0.6 |
| EBT, Incl. Unusual Items | (63.1) | (83.5) | (117.8) | (131.0) | (122.2) | (107.6) | (35.0) | 45.6 | 93.1 | 26.9 | 32.6 | 125.5 | 19.3 | — |
| Income Tax Expense | 0.1 | (1.7) | (1.7) | 2.8 | (0.4) | (28.6) | 1.1 | (0.8) | 21.2 | 9.2 | 10.9 | 46.5 | (15.2) | 0.0 |
| Net Income | ||||||||||||||
| Net Income | (63.2) | (81.9) | (116.0) | (133.8) | (121.8) | (79.0) | (36.2) | 46.4 | 72.0 | 17.7 | 21.7 | 79.0 | 34.4 | 9.6 |
| Per Share | ||||||||||||||
| Basic EPS | (2.17) | (3.84) | (5.48) | (6.38) | (5.91) | (3.92) | (1.81) | 2.37 | 3.74 | 0.93 | 1.14 | 4.23 | 1.88 | (0.67) |
| Diluted EPS | (2.17) | (3.84) | (5.48) | (6.38) | (5.91) | (3.92) | (1.81) | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | (0.67) |
| Revenue per Share | 2.24 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 29.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19.6 | 19.3 | 19.1 | 18.9 | 18.7 | 0.0 | 9.8 |
| Diluted Weighted Avg Shares | 29.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.0 | 20.7 | 19.4 | 19.2 | 19.3 | 0.0 | 9.8 |
| Supplemental | ||||||||||||||
| EBITDA | — | (80.8) | (119.4) | (134.8) | (120.9) | (106.2) | (38.0) | 40.0 | 90.8 | 26.8 | 32.5 | 124.8 | 19.3 | 9.3 |
| EBIT | (58.7) | (85.3) | (121.7) | (137.2) | (123.8) | (109.6) | (41.6) | 36.7 | 88.3 | 24.6 | 30.8 | 124.1 | 19.0 | 9.0 |
| Effective Tax Rate | -0.2% | — | — | -2.2% | 0.4% | 26.6% | -3.3% | -1.8% | 22.7% | 34.3% | 33.5% | 37.0% | -78.7% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.